Explore emerging therapeutic options for the management of anemia in patients with #MF, a current unmet need. #MPN #MPNsm

The MPN Hub spoke to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, about the current role of luspatercept in treating patients with MF and potential future directions. Watch the full video here: #MPM #MPNsm #myelofibrosis

🚨 The #MPN Hub will be attending #Tandem25 virtually! 📅 February 12–15  📍 Honolulu, US, and online Watch out for our updates and live social media coverage. #mpnsm @ASTCT @CIBMTR

📝 Final results from the phase II REVIVE trial, presented at #ASH24, found that rusfertide with or without CRT provided long-term durable hematocrit control and reduced the need for therapeutic phlebotomy in pts with PV. More news: #MPN #MPNsm #MedNews

What are the developments for treating anemia in pts with MF? The MPN Hub spoke to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, US, about the role of luspatercept in treating pts with MF and potential future directions. Watch here: #MPM #MPNsm

New data 📝 Final results from the phase II REVIVE trial presented at #ASH24 show that rusfertide provided long-term durable hematocrit control and reduced the need for therapeutic phlebotomy in patients with PV. Learn more: #MPN #MPNsm #MedNews #MedEd

Today is #WorldCancerDay! Our vision is for every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in #MPN to improve the lives of patients globally. Find out more: #mpnsm

📝 A new publication in Annals of Hematology details the planned phase IV PARADIGM-PV study, assessing a higher starting dose and reduced-intensity maintenance of ropeg on reducing phlebotomy dependence in pts with PV. More news: #MPN #MPNsm #MedNews

📝 Yacoub et al. detail the phase IV PARADIGM-PV study, which will assess a higher starting dose and reduced-intensity maintenance of ropeg on reducing phlebotomy dependence in pts with PV in Annals of Hematology. Learn more: #MPN #MPNsm #MedNews

📝 Results from the phase II RESTORE trial presented at #ASH24 found that elritercept was well tolerated and demonstrated hematologic improvements in patients with MF as a monotherapy and in combination with ruxolitinib. More news: #MPN #MPNsm #MedNews

In 2024, @US_FDA provided guidance on diversity action plans for clinical studies – find out how this is being put in to practice in our accredited virtual clinical trial club. Chaired by Paolo Gisondi, the webinar will focus on #ImprovingOutcomes for #PeopleOfColor with chronic plaque psoriasis including scalp involvement. Register here: #MedEd #DiversityInHealthcare

📝 Results from part I of the phase II Apex trial presented at #ASH24 found that bezuclastinib 100 mg BID was well tolerated, with an ORR of 83% in patients with advanced systemic mastocytosis. More news: #MPN #MedNews #MedEd

New data 📝 Results from the phase II RESTORE trial presented at #ASH24 show that elritercept was well tolerated as monotherapy and in combination with ruxolitinib and produced hematologic improvements in patients with MF. Learn more: #MPN #MPNsm

New data 📝 Results from part I of the phase II Apex trial presented by DeAngelo at #ASH24 showed that bezuclastinib 100 mg BID provided optimal efficacy and safety outcomes in patients with advanced systemic mastocytosis. Learn more: #MPN #MedNews #MedEd

What do you consider to be the highest unmet need for patients with myelofibrosis?

📝 Results from a matching-adjusted indirect comparison presented by Francesca Palandri at #ASH24 show that momelotinib improves OS vs BAT in patients with #MF who were previously treated with ruxolitinib. More news: #MPN #MPNsm #MedNews #MedEd

New data 📝 Results from a matching-adjusted indirect comparison presented by Francesca Palandri at #ASH24 show that momelotinib improves OS vs BAT in patients with #MF who were previously treated with ruxolitinib. Learn more: #MPN #MPNsm #MedNews #MedEd

📝 Results from the phase III MANIFEST-2 trial presented at #ASH24 found that pelabresib + ruxolitinib demonstrates long-term improvements in spleen volume, TSS, anemia, and bone marrow microenvironment in patients with MF. More news: #MPN #MPNsm #MedNews

New data 📝 Updated results from the phase III MANIFEST-2 trial presented by John Mascarenhas at #ASH24 show that pelabresib plus ruxolitinib shows long-term efficacy and safety in JAKI-naïve patients with MF. Learn more: #MPN #MPNsm #MedNews #MedEd

📝 Results from the retrospective PV-ARC study presented at #ASH24 suggested that ELN Clinical Signs and Symptoms can identify patients with PV at increased thrombotic risk across all conventional risk categories. More news: #MPN #MPNsm #MedNews #MedEd